Acurx Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

ACCOUNTS PAYABLE AND ACCRUED EXPENSES

6 Months Ended

Jun. 30, 2023

NOTE 3 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses as of June 30, 2023 and December 31, 2022 were as follows:


	June 30, 2023		December 31, 2022
Accrued compensation expenses	$	35,887	$	542,895
Accrued research and development		2,881,561		1,405,536
Accrued professional fees		89,081		83,715
Other accounts payable and accrued expenses		12,879		29,539
Total	$	3,019,408	$	2,061,685